Screener
Celldex Therapeutics CLDX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's accounts payable?
- Celldex Therapeutics (CLDX) reported accounts payable of $14.68M in Q2 2026.
- How has Celldex Therapeutics's accounts payable changed year-over-year?
- Celldex Therapeutics's accounts payable increased by 607.9% year-over-year, from $2.07M to $14.68M.
- What is the long-term trend for Celldex Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Celldex Therapeutics's accounts payable has grown at a 2.4% compound annual growth rate (CAGR), from $1.05M to $1.18M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Celldex Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude